Published in Clujul Med on January 15, 2016
Evaluation of liver fibrosis: a concise review. Am J Gastroenterol (2004) 4.37
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr (2005) 2.13
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol (2000) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology (2012) 1.92
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis (2007) 1.79
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol (2003) 1.64
Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl (2008) 1.49
Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology (2009) 1.47
Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology (2005) 1.42
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem (1996) 1.38
Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol (2005) 1.30
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol (2005) 1.27
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int (2005) 1.27
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol (2005) 1.25
Serum hyaluronate in primary biliary cirrhosis--a biochemical marker for progressive liver damage. Hepatology (1988) 1.24
Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol (2005) 1.21
Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol (2005) 1.19
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr (2010) 1.13
Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol (2003) 1.09
Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int (2006) 1.06
Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2006) 1.04
Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology (1996) 1.03
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One (2011) 1.02
Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res (2005) 1.02
Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol (1995) 1.01
Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J Gastroenterol (2008) 0.99
Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int (2006) 0.97
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2007) 0.93
Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol (2011) 0.93
Measurement of serum hyaluronic acid as a sensitive marker of liver fibrosis in biliary atresia. J Pediatr Surg (2000) 0.92
Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis (2010) 0.90
Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol (2004) 0.90
Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol (2000) 0.90
Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol (2008) 0.90
Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. Arch Dis Child (2002) 0.89
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology (2004) 0.89
Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PLoS One (2015) 0.89
Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients. Mediators Inflamm (2001) 0.88
Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat (2009) 0.88
Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis (2012) 0.87
Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease. J Korean Med Sci (2009) 0.87
Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. J Dig Dis (2012) 0.86
Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology (1996) 0.86
Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. J Hepatol (2001) 0.86
Hyaluronic acid: a specific prognostic indicator of hepatic damage in biliary atresia. J Pediatr Surg (1999) 0.86
Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int (2004) 0.85
Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. Antivir Ther (2013) 0.85
Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS One (2014) 0.84
Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol (2006) 0.84
Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol (1996) 0.83
Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis. Braz J Infect Dis (2010) 0.82
Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci (2000) 0.82
T cell immune response is correlated with fibrosis and inflammatory activity in hepatitis B cirrhotics. World J Gastroenterol (2006) 0.81
Evaluation of serum hyaluronic acid level and hyaluronidase activity in acute and chronic hepatitis C. J Int Med Res (2007) 0.80
Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int (2008) 0.80
Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat (2008) 0.79
Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. PLoS One (2014) 0.78
Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int (2013) 0.78
Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease. J Gastrointestin Liver Dis (2015) 0.78
Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients. Int Urol Nephrol (2015) 0.76
Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome. J Intern Med (1992) 0.76
Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis. J Gastroenterol Hepatol (1996) 0.76
Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci (2015) 0.76
Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: an Egyptian study. World J Gastroenterol (2013) 0.76
Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int (2015) 0.76
A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study. Pol Arch Med Wewn (2014) 0.75
Anxiety and IBS revisited: ten years later. Clujul Med (2015) 0.76
Romanian version of the oral health impact profile-49 questionnaire: validation and preliminary assessment of the psychometrical properties. Clujul Med (2015) 0.75
Small Intestinal Bacterial Overgrowth is Associated with Intestinal Inflammation in the Irritable Bowel Syndrome. Clujul Med (2014) 0.75
Serum biomarkers for irritable bowel syndrome. Clujul Med (2015) 0.75